Results 1 to 10 of about 2,965 (184)

Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes [PDF]

Annals of Hematology
Graft versus host disease (GVHD) is a serious side effect of allogenic stem cell transplantation (allo-SCT). Anti-thymocyte globulin (ATG) reduces GVHD but raises the risk of infections following allo-SCT.
Shuto Negishi, Kotaro Miyao, Fumiya Ohara, Kenta Motegi, Hiroya Wakabayashi, Hitomi Sawa, Yuichiro Inagaki, Masashi Sawa   +7 more
doaj   +2 more sources

Letermovir for cytomegalovirus prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation: a single-center experience [PDF]

Blood Research
Purpose Letermovir prophylaxis results in a significantly lower risk of clinically significant cytomegalovirus (CMV) infection in adult hematopoietic stem cell transplant recipients.
Pai-Lin Tsai, Meng-Yao Lu, Hsiu-Hao Chang, Yung-Li Yang, Chia-Jui Du, Chang-Hsueh Wu, Shiann-Tarng Jou, Shu-Wei Chou   +7 more
doaj   +2 more sources

Refining letermovir prophylaxis strategies and CD4 + T cell-guided discontinuation in aplastic anemia patients post-allogeneic HSCT: a retrospective analysis [PDF]

European Journal of Medical Research
Introduction Cytomegalovirus (CMV) infection is a significant complication in aplastic anemia (AA) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Yuling Zhang, Xiaoqing He, Ming Zhou, Yuping Zhang, Wenjian Mo, Ruiqing Zhou, Yumiao Li, Qi Xiang, Fangfang Yang, Shilin Xu, Caixia Wang, Wei Zhou, Tingfen Deng, Shiyi Pan, LiangLiang Wu, Shunqing Wang, Xiaowei Chen   +16 more
doaj   +2 more sources

Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study [PDF]

Frontiers in Cellular and Infection Microbiology
ObjectivesTo compare the efficacy and safety of letermovir and ganciclovir for cytomegalovirus (CMV) prophylaxis in adolescent patients (aged 14-17 years) undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT).MethodsThis observational ...
Ziwei Xu, Xuan Lu, Huafang Wang
doaj   +2 more sources

Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis [PDF]

Experimental Hematology & Oncology
Letermovir is an antiviral agent that significantly decreases the frequency of cytomegalovirus (CMV) infections following allogeneic hematopoietic stem cell transplantation (allo-HCT); however, its impact on Epstein-Barr virus (EBV) infection remains ...
Jingtao Huang, Jing Zhou, Shixuan Zhang, Ruoxuan Zhang, Zengkai Pan, Luxiang Wang, Chuanhe Jiang, Jiayu Huang, Zilu Zhang, Yanmin Zhao, Yang Cao, Xiaoxia Hu   +11 more
doaj   +2 more sources

Evaluating valaciclovir, letermovir, and maribavir safety in first-trimester human placental development [PDF]

Scientific Reports
Congenital cytomegalovirus (CMV) infection is the leading preventable cause of childhood disability, including sensorineural hearing loss and cerebral palsy in high-income countries.
Ishara Atukorala, Natasha de Alwis, Sally Beard, Swetha Raghavan, Natalie J. Hannan, Lisa Hui   +5 more
doaj   +2 more sources

Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era – emerging humoral and cellular players [PDF]

Haematologica
Allogeneic hematopoietic stem cell transplant (alloSCT) recipients frequently experience late-onset human cytomegalovirus (HCMV) reactivations following termination of letermovir prophylaxis.
Chris D. Lauruschkat, Hannah Görge, Kerstin Knies, Benedikt Weißbrich, Lars Dölken, Carolin Köchel, Nina Imhof, Magdalena Huber, Hartmut Hengel, Hermann Einsele, Sebastian Wurster, Sabrina Kraus   +11 more
doaj   +2 more sources

Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients [PDF]

Drug Design, Development and Therapy
Yongbing Zhu,* Li Wang,* Yu Xiang, Yaqin Wang, Ai Zhang, Yao Wang, Mengmeng Yin, Jianxin Dun, Yuting Xu, Qun Hu, Wen Yu,* Aiguo Liu* Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University ...
Zhu Y, Wang L, Xiang Y, Wang Y, Zhang A, Wang Y, Yin M, Dun J, Xu Y, Hu Q, Yu W, Liu A   +11 more
doaj   +2 more sources

Revisiting cytomegalovirus in pediatric allogeneic hematopoietic stem cell transplant recipients: current strategies for prevention and management in the letermovir era [PDF]

Frontiers in Pediatrics
CMV infection remains the most common clinically significant infection in pediatric allogeneic hematopoietic stem cell (HCT) recipients, with seropositive recipients of transplants from seronegative donors at the highest risk for complications. In recent
Lisa Hiskey, Diego R. Hijano, Diego R. Hijano, Ramia Zakhour   +3 more
doaj   +2 more sources

Reversion of Val(Ganciclovir)-Resistance-Associated Mutations in Two SOT Patients with Mismatched Serostatus for CMV (D+/R-) [PDF]

Viruses
The emergence of drug-resistant cytomegalovirus (CMV) complicates viral response to therapy. We present two cases of solid organ transplant (SOT) recipients, highlighting the reversion of UL97 mutations associated with val(ganciclovir) resistance ...
Elena Seminari, Alessandra Tebaldi, Aurelia Sangani, Paola Giordani, Daniele Lilleri, Stefania Paolucci, Giulia Campanini, Elizabeth Iskandar, Fausto Baldanti, Raffaele Bruno   +9 more
doaj   +2 more sources